Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717624 · ClinicalTrials.gov registry record · Phase 1
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
A Phase 1 study of Mantle Cell Lymphoma (MCL), sponsored by Acerta Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 15
- Study locations
NCT02717624: Active Phase 1 study of Mantle Cell Lymphoma (MCL), sponsored by Acerta Pharma.
NCT02717624 is a Phase 1 study of Mantle Cell Lymphoma (MCL) that is active but no longer recruiting, run by Acerta Pharma. The registered enrollment target is 72 participants, below the 201-participant average among 9 other Mantle Cell Lymphoma (MCL) trials with a reported enrollment target (64% lower). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02717624, a Phase 1 study of Mantle Cell Lymphoma (MCL), is active but no longer recruiting, sponsored by Acerta Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 15
- Study locations
Study Summary
A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma
Primary Outcome
Number of participants who had experienced at least one treatment emergent AE
Conditions Studied
Interventions
- DRUG Acalabrutinib in combination with BR
- DRUG Acalabrutinib in combination with VR
Study Locations (15)
Other
- Research Site - Bologna
- Research Site - Krakow
- Research Site - Lodz
- Research Site - Olsztyn
- Research Site - Warsaw
New Jersey
- Research Site - Hackensack
- Research Site - Morristown
Washington
- Research Site - Seattle
- Research Site - Seattle
Kentucky
- Research Site - Louisville
Michigan
- Research Site - Ann Arbor
New York
- Research Site - Lake Success
Ohio
- Research Site - Columbus
Tennessee
- Research Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-04-20 |
| Est. Completion | 2027-08-20 |
| Phase | Phase 1 |
What the registry record for NCT02717624 still lists
NCT02717624 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 201-participant average among 9 other Mantle Cell Lymphoma (MCL) trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Mantle Cell Lymphoma (MCL) appearing as the primary indexed condition, and to 2 interventions - of which Acalabrutinib in combination with BR is the first listed.
NCT02717624 lists 15 locations in 9 states (Other, New Jersey, Washington).
Frequently Asked Questions
What is clinical trial NCT02717624 about?
NCT02717624 is a clinical study titled "A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL". A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma
What is the current status of trial NCT02717624?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2016-04-20. Estimated completion is 2027-08-20.
What conditions does trial NCT02717624 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma (MCL).
What interventions are being tested in trial NCT02717624?
The interventions under investigation include: Acalabrutinib in combination with BR (DRUG), Acalabrutinib in combination with VR (DRUG).
Who is sponsoring clinical trial NCT02717624?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02717624 being conducted?
This trial has 15 study locations across Kentucky, Michigan, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma (MCL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02717624's enrollment target sits among peer trials
72 8th of 9 higher than 2 of 9 other Mantle Cell Lymphoma (MCL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma (MCL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DALY II USA/ MB-CART2019.1 for DLBCL
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI